Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults and can be primary or secondary. Primary MN is most commonly associated with anti−M-type phospholipase A2 receptor (PLA2R) antibodies and is usually IgG4 dominant, whereas secondary MN can be seen in the setting of malignancies, infections, autoimmune diseases, or as a side effect of certain medications or toxins, and is most commonly IgG1 dominant.[@bib1]^,^[@bib2] The occurrence of crescents in MN is extremely rare, with a prevalence estimated between 0.39%[@bib3] and 0.26%.[@bib4] Crescents can be seen in both primary and secondary MN[@bib3], [@bib4], [@bib5] or in association with a superimposed disease process, such as anti−neutrophil cytoplasmic antibody (ANCA)−associated glomerulonephritis or anti−glomerular basement membrane (GBM) disease. Previous series in the United States have either focused on cases of MN with crescents in the absence of ANCAs or anti-GBM antibodies,[@bib3] or in association with ANCAs.[@bib5] In light of the recently published series of MN with crescents from the United Kingdom,[@bib4] and given the rarity of this entity, we analyzed its prevalence and its clinical and pathological characteristics in biopsy findings reviewed at our institution.

A total of 14,800 native and transplant renal biopsy specimens were received at the Ohio State University from 2010 to 2019. Of these, 15 cases (0.1%) showed MN with crescents (fibrous crescents only, 3; diffuse crescents \[in \>50% of glomeruli\], 3; focal crescents \[in \<50% of glomeruli\], 9). In addition, 3 cases had only segmental subepithelial deposits (segmental MN). Cases of lupus nephritis were excluded. PLA2R staining was performed retrospectively in 7 cases.

There were 8 female and 7 male patients. Two had anti-GBM antibodies ([Figure 1](#fig1){ref-type="fig"}a--d), 9 had ANCAs (8 MPO, 2 both MPO and PR3), and 4 showed anti-PLA2R−positive deposits in the biopsy specimen ([Figure 1](#fig1){ref-type="fig"}e--g), including 1 with positive serum anti-PLA2R. Of note, not all of these antibodies were checked in all patients. Clinical features are summarized in [Table 1](#tbl1){ref-type="table"} and pathological features in [Table 2](#tbl2){ref-type="table"}. One patient had prior ANCA-associated cutaneous vasculitis, and 1 patient had prior biopsy-proven infection-related glomerulonephritis; both had a history of cocaine use. Potential secondary causes of MN included solid organ malignancies (n =3), hepatitis C (n = 2), and rheumatoid arthritis (n = 1). Three patients had a monoclonal gammopathy of undetermined significance, and 5 patients had positive autoantibodies (4 anti−nuclear antibodies, 2 anticardiolipin, and 2 anti-SSB). Eight patients had pulmonary symptoms, including hemoptysis in 3 and documented diffuse alveolar hemorrhage in 2. Twelve patients had hematuria, which was usually significant, and 14 had proteinuria (1 patient was anuric). Proteinuria was measured by spot urine protein-to-creatinine ratio or 24-hour collection and was \>3 g in 7 of the 14 patients. Median creatinine at presentation was 2.9 mg/dl (1.07−18.6). Two patients had normal renal function on presentation (1 patient had a single fibrous and the other a single cellular crescent). The remaining 13 patients had estimated glomerular filtration rate of \<60 ml/min per 1.73 m^2^. Eleven patients presented with severe kidney dysfunction (eGFR ≤30 ml/min per 1.73 m^2^), 4 of whom required dialysis (2 with anti-GBM and 2 with MPO). Twelve patients received immunosuppression, 2 did not (1 had end-stage renal disease \[ESRD\]), and the other had a single fibrous crescent on biopsy); treatment data were not available for 1 patient. The most common drugs used were corticosteroids (n = 11) and cyclophosphamide (n = 10), followed by mycophenolate mofetil (MMF) (n = 4), azathioprine (n = 1), and rituximab (n = 1). Plasmapheresis was performed in 3 patients: 2 with anti-GBM and 1 with myeloperoxidase (MPO) antibodies and hemoptysis. Follow-up data were available for 13 patients, with a median follow-up of 38 months (4−98 months). Of these 13 patients, 5 reached ESRD (3 MPO, 2 anti-GBM), of whom 3 received a kidney transplant. Of the patients who reached ESRD, 2 had \>50% crescents on biopsy, and 1 patient had \>90% interstitial fibrosis and tubular atrophy (IFTA); the other 2 patients had up to 25% crescents and 25% to 35% IFTA ([Table 2](#tbl2){ref-type="table"}). Five patients developed chronic kidney disease, 2 died (both had solid organ malignancies), and only 3 (20%) had eGFR \>60 ml/min 1.73 m^2^ (all of these patients had only focal crescents and mild IFTA on biopsy). Conversely, renal survival in MN without crescents is estimated to be between 70% and 90%.[@bib6]Figure 1Top row (a--d): a case of anti--glomerular basement membrane (GBM) disease (case 12) with segmental membranous nephropathy (MN). (a) Glomerulus with a cellular crescent (hematoxylin and eosin \[H&E\] stain, original magnification ×400). (b) Silver stain shows a compressed glomerular tuft with no obvious spikes or lucencies along the GBM (original magnification ×4000). (c) Linear IgG staining (immunofluorescence, original magnification ×400). (d) Electron microscopic image showing segmental subepithelial deposits. Bottom row (e−h): a case of PLA2R-positive MN with concomitant p-ANCA (case 8). (e) Glomerulus with a cellular crescent (H&E stain, original magnification ×400). (f) Silver stain highlights capillary wall irregularities (fine lucencies and spikes) in the same glomerulus that contains a cellular crescent (original magnification ×400). (g) An anti-PLA2R antibody shows diffuse granular positivity along the GBM (immunofluorescence, original magnification ×400). (h) Electron microscopy confirms diffuse subepithelial deposits.Table 1Clinical characteristicsCaseSexAge (yr)EthnicityBaseline Cr (mg/dl)Cr at biopsy (mg/dl)GFR at diagnosis (ml/min per 1.73 m^2^)HematuriaProteinuria at biopsyFollow-up proteinuriaAlbumin (g/dl)EdemaLung symptomsMedical comorbiditiesAntibodiesOther relevant labsTreatmentDialysisTransplantCr at last follow-up (mg/dl)GFR at follow-up (ml/min per 1.73 m^2^)Follow-up duration (mo)1F68White1.6943+4 g/24 hNA2.5YesSOBRheumatoid arthritis, NSAID useMPONACyclophosphamide, prednisone complicated by aspergillus pneumoniaYesYesNANANA2F21WhiteNA153AnuricAnuricESRDNANADAH, acute respiratory failureNAAnti-GBMNAPLEX, prednisone, and cyclophosphamideYesNoESRDESRD473M65White0.92.230\>100 RBCs/HPF2.89g/24hESRD3.7NoHemoptysisRaynaud syndromepANCA, MPOANA 1:80prednisone, MMF switched to cyclophosphamide, PLEX, then azathioprine and prednisoneYesYesESRD (5.38) after transplant nephrectomyESRD984F64AA22.524Moderate, 20−29 RBCs/HPF1.6 g/24h1.1 g UPC2.2YesHemoptysis, DAHDiabetes, hep C cirrhosis, HCCpANCA, MPO, PR3ANA 1:320, +anticardiolipin IgM, c3 77, c4 14Prednisone and cyclophosphamide then MMFNoNone4.33 Deceased12135F62AsianNA1.0951NA16.9g/24hNA0.6YesNALiver dysfunctionNANANoneNANA1.1449796F61AA0.895Few RBCs8 g UPC1.6 g/ 24 h1.4YesPulmonary noduleHTN, CKD, heavy smokerNANAPrednisone and cyclophosphamideNoNo1.3249107F66AA1.32.920NA3.5 g UPCNANANANABladder cancer, MGUSpANCANANANANANANANA8M70White1.32.3528\>20 RBCs/HPF2 g/24 h1.3 g UPC3.4NoCoughPrevious MN with crescents, MGUS, resected pancreatic neoplasm, metastatic sarcomatoid carcinoma, HTN, DMpANCA, MPO, PR3Minute IgG KPrednisone and cyclophosphamideNoNo1.99 Deceased33149M79White1.532121−30 RBCs/HPF1 g UPC0.2 g UPC4.5NoNoneHTN, MGUS, diabetespANCA, MPONoneCyclophosphamide, prednisone, then MMFNoNo2.023246 mo10M56AA1.071.07\>60Large4.7 g/24 h0.7 g/ 24 h2.7YesNoneDiabetes, HTNNANoneCyclophosphamideNoNo0.83\>6049 mo11F42NA11.8NA\>60 RBCs/HPF1.8 g UPC0.2 g UPC1.7NANAPrior MPO-ANCA cutaneous vasculitis, history of cocaine abuse, positive MRSA skin cultureMPOPositive ANA and anti-SSBPrednisone, MMFNANA0.8\>6041 mo12M26WhiteNA18.63Large2.8 g/24 h0.07 g UPC3.6NoneHemoptysisObesityAnti-GBM \>8NonePLEX, steroids, cyclophosphamideYesYes2.013938 mo13M34AA1.031.189345 RBCs/HPF1.8 g UPC1.2 g UPC3.8NANAHTN, obesitypANCA, MPOANA 1:40Prednisone, rituximabNoNo0.9811328 mo14M41White1.810.95Large9.5 g UPCESRD2.5NoneNAPrior infection-related GN, i.v. drug use (including cocaine), hep C, endocarditis, seizurepANCA, MPOPositive anticardiolipin and anti-SSBNoneYesNoESRD (10.2)ESRD4 mo15F20AA0.833243−5 RBCs/HPF24.8 g/24 h3.4 g UPC1.4YesSOBSchizophrenia, bipolar disorder, Bell palsy, obesityAnti-PLA2R antibodyLow C4 (17), normal C3Prednisone, cyclophosphamideNoNo1.515217 mo[^1]Table 2Pathological characteristicsCaseFinal diagnosisTotal glomeruliCrescents/FNGS% Active lesions[a](#tbl2fna){ref-type="table-fn"}IFTA%Immunofluorescence[b](#tbl2fnb){ref-type="table-fn"}IgG1IgG2IgG3IgG4PLA2REM stageMesangial depositsTRIsExtraglomerular deposits1ANCA-associated crescentic and necrotizing GN; membranous GN16482525IgG, IgA, C3, kappa, lambda GBM101.50.5NegativeNANANA02Diffuse crescentic and necrotizing anti-GBM disease; segmental MN21180850Linear GBM IgG, kappa and lambda; linear TBM IgG (focal)2.5 Linear1.5 Linear03 LinearNegative10003Focal crescentic GN with MN30110335IgG, IgA, C3, kappa, lambda GBM and mesangial; IgG, kappa, lambda TBM1.5100.5Negative1 to 210TBM deposits by IF4MN with fibrous crescents; underlying diabetic glomerulosclerosis244 (Fibrous)10060-70IgG, IgM, C1q, C3, kappa and lambda GBM, IgG TBM (focal)1.50.50.52Positive3 to 400TBM deposits by IF5MN with fibrous crescents341 (Fibrous)9020IgG, C3, kappa, lambda GBM3202Negative20006MN with focal crescents13302320-25IgG, IgA, IgM, C1q, C3, Kappa and lambda GBM2123Weak and segmental2 to 30007ANCA-associated crescentic and necrotizing GN with MN338122460IgG, IgM, kappa, lambda GBM210.53Positive2 to 30008ANCA-associated crescentic and necrotizing GN; membranous GN12605030IgG, C3, kappa, lambda GBM1.50.510Negative1 to 40009ANCA-associated necrotizing and crescentic GN with MN and TBM deposits5102035IgG, kappa, lambda GBM; IgG, C1q, kappa, lambda TBM (focal)10.502Negative1 to 300TBM deposits by IF and EM10MN with focal crescents121285IgG, C3, kappa and lambda3123Positive200011Immune-complex GN with segmental MN and focal necrotizing lesions13201510IgG, IgM, C3, kappa and lambda GBM and segmental mesangial20.50.50Negative2Rare1012Diffuse crescentic and necrotizing anti-GBM disease; segmental MN231807825Linear IgG, IgA, C3, kappa and lambda2 Linear1 Linear1 Linear2 LinearNegative1 to 200013MN with focal crescents4217220IgG, C3, kappa and lambda GBM210.52Negative1 to 200014Advanced chronic renal injury with underlying MN; acute TMA325 (Fibrous)29090IgG, IgM, C3, kappa and lambda GBM and mesangial10.50.50Negative210015MN with focal crescents9303320IgG, C3, kappa and lambda GBM and mesangial3123Positive2 to 4111[^2][^3][^4]

Overall, our series findings are similar to those recently reported by Nikolopoulou *et al.*,[@bib4] with approximately 40% of patients reaching ESRD. We had a greater number of anti-PLA2R−positive cases (26% vs. 13%), whereas they had a greater number of anti-GBM−positive patients (33% vs. 13%). Interestingly, however, outcomes were similar, which may be due to the fact that the prognosis of anti-GBM disease tends to be better in cases with associated MN,[@bib7] with close to 40% of patients recovering renal function[@bib8] in contrast to only 15% in pure anti-GBM disease.[S1](#appsec1){ref-type="sec"} Potential explanations for that could be overall lower levels of anti-GBM antibodies in patients with concomitant MN as well as a narrower antigen reactivity spectrum of the anti-GBM antibodies present.[@bib7]

In contrast to MN without crescents, in which case \>90% of patients have normal renal function at presentation[@bib1] and hematuria is generally microscopic and low-grade,[S2](#appsec1){ref-type="sec"} most of our patients had significant hematuria, and approximately 75% presented with severe kidney dysfunction. In addition, although approximately 80% of cases of MN without crescents are considered primary, in our series only 26% of cases were PLA2R positive, and 40% were IgG4 dominant/co-dominant. Therefore, it appears that crescents occur more often in cases of secondary MN.

In conclusion, MN with crescents is a rare and heterogeneous entity that can be associated with ANCA, anti-GBM, PLA2R, and potentially other autoantibodies. It presents more often with significant hematuria and renal dysfunction than MN without crescents and progresses more often to ESRD. Whether these cases represent a coincidental occurrence of 2 separate disease entities or whether they are pathogenically related remains to be determined,[@bib8] although the latter is conceivable. For example, subepithelial deposits may facilitate GBM damage, leading to anti-GBM antibody production. Conversely, GBM damage caused by anti-GBM (or other) antibodies could expose epitopes that lead to immune-complex deposition along the subepithelial aspect of the GBM.
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**Supplementary References.**

[^1]: AA, African American; ANA, anti−nuclear antibodies; ANCA, anti−neutrophil cytoplasmic antibodies; Cr, creatinine; C3, complement factor 3; C4, complement factor 4; CKD, chronic kidney disease; DAH, diffuse alveolar hemorrhage; DM, diabetes mellitus; ESRD, end-stage renal disease; F, female; GBM, glomerular basement membrane; GFR, glomerular filtration rate; GN, glomerulonephritis; HCC, hepatocellular carcinoma; hep C, hepatitis C; HPF, high-power field; HTN, hypertension; labs, laboratory investigations; M, male; MGUS, monoclonal gammopathy of undetermined significance; MMF, mycophenolate mofetil; MN, membranous nephropathy; MPO, myeloperoxidase; MRSA, methicillin-resistant *Staphylococcus aureus*; NA, not available; NSAIDs, nonsteroidal anti-inflammatory drugs; PLA2R, M-type phospholipase A2 receptor; PLEX, plasma exchange; PR3, proteinase 3; RBCs, red blood cells; SOB, shortness of breath; SSB, anti-Sjögren\'s syndrome type B; UPC, urine protein-to-creatinine ratio.

[^2]: ANCA, anti−neutrophil cytoplasmic antibodies; C3, complement factor 3; C4, complement factor 4; Ig, immunoglobulin; EM, electron microscopy; FN, fibrinoid necrosis; GBM, glomerular basement membrane; GN, glomerulonephritis; GS, globally sclerotic glomeruli; IFTA, interstitial fibrosis and tubular atrophy; MN, membranous nephropathy; PLA2R, M-type phospholipase A2 receptor; NA, not available; TBM, tubular basement membrane; TMA, thrombotic microangiopathy; TRIs, tubuloreticular inclusions.

[^3]: Active lesions include cellular or fibrous−cellular crescents and areas of glomerular segmental fibrinoid necrosis.

[^4]: Deposits are granular unless otherwise specified.
